The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
PharmGKB summary: cyclosporine and tacrolimus pathways
Open accessAbstract
Barbarino, Julia M.; Staatz, Christine E.; Venkataramanan, Raman; Klein, Teri E.; Altman, Russ B. Author Information
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yu, S., Wu, L., Jin, J., Yan, S., Jiang, G., Xie, H., & Zheng, S. (2006) · Transplantation · doi:10.1097/01.tp.0000188118.34633.bf · Cited by 76
RetractedKyriakis, J. M., & Avruch, J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.807 · Cited by 3,382
The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases
Karin, M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16483 · Cited by 2,431
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,365
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
Self-citationNF-κB, the first quarter-century: remarkable progress and outstanding questions
Hayden, M. S., & Ghosh, S. (2012) · Genes & Development · doi:10.1101/gad.183434.111 · Cited by 1,693
The role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3156 · Cited by 1,657
Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation
Clipstone, N. A., & Crabtree, G. R. (1992) · Nature · doi:10.1038/357695a0 · Cited by 1,637
Calcineurin Inhibitor Nephrotoxicity
Naesens, M., Kuypers, D. R. J., & Sarwal, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04800908 · Cited by 1,489
Calcineurin: Form and Function
Rusnak, F., & Mertz, P. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.4.1483 · Cited by 1,373
KINO, T., HATANAKA, H., MIYATA, S., INAMURA, N., NISHIYAMA, M., YAJIMA, T., GOTO, T., OKUHARA, M., KOHSAKA, M., AOKI, H., et al. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1256 · Cited by 1,209
Pirsch, J. D., Miller, J., Deierhoi, M. H., Vincenti, F., & Filo, R. S. (1997) · Transplantation · doi:10.1097/00007890-199704150-00013 · Cited by 1,122
Pharmacogenetics: From Bench to Byte— An Update of Guidelines
Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., Rongen, G. A. P. J. M., van Schaik, R. H. N., Schalekamp, T., Touw, D. J., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.34 · Cited by 1,018
Genetic contribution to variable human CYP3A-mediated metabolism
Lamba, J. K., Lin, Y. S., Schuetz, E. G., & Thummel, K. E. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00066-2 · Cited by 990
Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation
Staatz, C. E., & Tett, S. E. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443100-00001 · Cited by 913
Self-citationWacher, V. J., Wu, C., & Benet, L. Z. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940130302 · Cited by 857
Mechanisms of action of cyclosporine
Matsuda, S., & Koyasu, S. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00192-2 · Cited by 812
Clinical Pharmacokinetics of Tacrolimus
Venkataramanan, R., Swaminathan, A., Prasad, T., Jain, A., Zuckerman, S., Warty, V., McMichael, J., Lever, J., Burckart, G., & Starzl, T. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529060-00003 · Cited by 808
Self-citationTransforming growth factor-β in T-cell biology
Gorelik, L., & Flavell, R. A. (2002) · Nature Reviews Immunology · doi:10.1038/nri704 · Cited by 792
Human P-glycoprotein transports cyclosporin A and FK506.
Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., & Komano, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53221-x · Cited by 684
Lown, K. S., Mayo, R. R., Leichtman, A. B., Hsiao, H.-L., Turgeon, D. K., Schmiedlin-Ren, P., Brown, M. B., Guo, W., Rossi, S. J., Benet, L. Z., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90027-8 · Cited by 680
Hesselink, D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00168-1 · Cited by 655
Webster, A. C., Woodroffe, R. C., Taylor, R. S., Chapman, J. R., & Craig, J. C. (2005) · BMJ · doi:10.1136/bmj.38569.471007.ae · Cited by 587
Transcriptional regulation of the IL-2 gene
Jain, J. (1995) · Current Opinion in Immunology · doi:10.1016/0952-7915(95)80107-3 · Cited by 565
Targeting dual-specificity phosphatases: Manipulating MAP kinase signalling and immune responses
Jeffrey, K. L., Camps, M., Rommel, C., & Mackay, C. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2289 · Cited by 533
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
Wang, D., Guo, Y., Wrighton, S. A., Cooke, G. E., & Sadee, W. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.28 · Cited by 505
Clinical Pharmacokinetics of Cyclosporin
Ptachcinski, R. J., Venkataramanan, R., & Burckart, G. J. (1986) · Clinical Pharmacokinetics · doi:10.2165/00003088-198611020-00002 · Cited by 493
Self-citationMultidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability
Wang, D., Johnson, A. D., Papp, A. C., Kroetz, D. L., & Sadée, W. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000178311.02878.83 · Cited by 490
Wallemacq, P., Armstrong, V. W., Brunet, M., Haufroid, V., Holt, D. W., Johnston, A., Kuypers, D., Meur, Y. L., Marquet, P., Oellerich, M., et al. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318198d092 · Cited by 468
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis
Ogata, H., Matsui, T., Nakamura, M., Iida, M., Takazoe, M., Suzuki, Y., & Hibi, T. (2006) · Gut · doi:10.1136/gut.2005.081794 · Cited by 462
Haufroid, V., Mourad, M., Van Kerckhove, V., Wawrzyniak, J., De Meyer, M., Eddour, D. C., Malaise, J., Lison, D., Squifflet, J.-P., & Wallemacq, P. (2004) · Pharmacogenetics · doi:10.1097/00008571-200403000-00002 · Cited by 447
Mode of Action of Tacrolimus (FK506): Molecular and Cellular Mechanisms
Thomson, A. W., Bonham, C. A., & Zeevi, A. (1995) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199512000-00007 · Cited by 439
Interaction of NF-κB and NFAT with the Interferon-γ Promoter
Sica, A., Dorman, L., Viggiano, V., Cippitelli, M., Ghosh, P., Rice, N., & Young, H. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.48.30412 · Cited by 429
First-pass metabolism of cyclosporin by the gut
Kolars, J. C., Watkins, P. B., Merion, R. M., & Awni, W. M. (1991) · The Lancet · doi:10.1016/0140-6736(91)92302-i · Cited by 422
Transcriptional regulation in the immune system: all roads lead to AP-1
Foletta, V. C., Segal, D. H., & Cohen, D. R. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.63.2.139 · Cited by 390
Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing
Thervet, E., Loriot, M. A., Barbier, S., Buchler, M., Ficheux, M., Choukroun, G., Toupance, O., Touchard, G., Alberti, C., Le Pogamp, P., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.17 · Cited by 369
Cyclosporin Clinical Pharmacokinetics
Fahr, A. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324060-00004 · Cited by 356
Shaw, K. T., Ho, A. M., Raghavan, A., Kim, J., Jain, J., Park, J., Sharma, S., Rao, A., & Hogan, P. G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.11205 · Cited by 345
Staatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317550-000000000-00000 · Cited by 343
Self-citationStaatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317350-000000000-00000 · Cited by 336
Self-citationCalcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B.
Frantz, B., Nordby, E. C., Bren, G., Steffan, N., Paya, C. V., Kincaid, R. L., Tocci, M. J., O'Keefe, S. J., & O'Neill, E. A. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06329.x · Cited by 334
Macian, F. (2000) · The EMBO Journal · doi:10.1093/emboj/19.17.4783 · Cited by 329
Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus
Christians, U., Jacobsen, W., Benet, L. Z., & Lampen, A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241110-00003 · Cited by 323
Kappa B-Specific DNA Binding Proteins: Role in the Regulation of Human Interleukin-2 Gene Expression
Hoyos, B., Ballard, D. W., Böhnlein, E., Siekevitz, M., & Greene, W. C. (1989) · Science · doi:10.1126/science.2497518 · Cited by 318
Yokota, M., Ichihara, S., Lin, T.-L., Nakashima, N., & Yamada, Y. (2000) · Circulation · doi:10.1161/01.cir.101.24.2783 · Cited by 299
Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery
Benet, L. Z., Izumi, T., Zhang, Y., Silverman, J. A., & Wacher, V. J. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00034-6 · Cited by 292
Hebert, M. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00043-4 · Cited by 288
Anglicheau, D., Verstuyft, C. A. A., Laurent-Puig, P., Becquemont, L., Schlageter, M.-H. A. A. G. A., Cassinat, B., Beaune, P., Legendre, C., & Thervet, E. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000073901.94759.36 · Cited by 281
EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO
Dai, Y., Hebert, M. F., Isoherranen, N., Davis, C. L., Marsh, C., Shen, D. D., & Thummel, K. E. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008680 · Cited by 279
Lampen, A., Christians, U., Guengerich, F. P., Watkins, P. B., Kolars, J. C., Bader, A., Gonschior, A. K., Dralle, H., Hackbarth, I., & Sewing, K. F. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06862-x · Cited by 273
Lemaire, M., & Tillement, J. P. (1982) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1982.tb06206.x · Cited by 265
Metabolism of Tacrolimus (FK506) and Recent Topics in Clinical Pharmacokinetics
Iwasaki, K. (2007) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.22.328 · Cited by 264
Therapeutic Monitoring of Calcineurin Inhibitors for the Nephrologist
Schiff, J., Cole, E., & Cantarovich, M. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03791106 · Cited by 257
Significance of the Minor Cytochrome P450 3A Isoforms
Daly, A. K. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645010-00002 · Cited by 254
Elens, L., Bouamar, R., Hesselink, D. A., Haufroid, V., van der Heiden, I. P., van Gelder, T., & van Schaik, R. H. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.165613 · Cited by 245
Clinically Significant Drug Interactions with Cyclosporin: An Update
Campana, C., Regazzi, M. B., Buggia, I., & Molinaro, M. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630020-00004 · Cited by 231
Patient management by Neoral C2 monitoring: An international consensus statement1
Levy, G., Thervet, E., Lake, J., & Uchida, K. (2002) · Transplantation · doi:10.1097/00007890-200205151-00003 · Cited by 227
NFAT pulls the strings during CD4+ T helper cell effector functions
Hermann-Kleiter, N., & Baier, G. (2010) · Blood · doi:10.1182/blood-2009-10-233585 · Cited by 218
Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus
Kamdem, L. K., Streit, F., Zanger, U. M., Brockmöller, J., Oellerich, M., Armstrong, V. W., & Wojnowski, L. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.050047 · Cited by 218
NADPH-Cytochrome P450 Oxidoreductase
Hubbard, P. A., Shen, A. L., Paschke, R., Kasper, C. B., & Kim, J.-J. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101731200 · Cited by 216
Matsuda, S., Moriguchi, T., Koyasu, S., & Nishida, E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.20.12378 · Cited by 213
Kuypers, D. R. J., de Jonge, H., Naesens, M., Lerut, E., Verbeke, K., & Vanrenterghem, Y. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100216 · Cited by 209
Grimm, M. F., Rinaldi, M., Yonan, N. A., Arpesella, G., del Prado, J. M. A., Pulpón, L. A. A., Villemot, J., Frigerio, M., Lambert, J. L., Crespo‐Leiro, M. G., et al. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01300.x · Cited by 196
CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation
Anglicheau, D. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.01.009 · Cited by 193
IN VIVO EXPRESSION OF TRANSFORMING GROWTH FACTOR-??1 IN HUMANS: Stimulation by Cyclosporine1
Shin, G.-T., Khanna, A., Ding, R., Sharma, V. K., Lagman, M., Li, B., & Suthanthiran, M. (1998) · Transplantation · doi:10.1097/00007890-199802150-00003 · Cited by 190
Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine
Burk, O., Tegude, H., Koch, I., Hustert, E., Wolbold, R., Glaeser, H., Klein, K., Fromm, M. F., Nuessler, A. K., Neuhaus, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202345200 · Cited by 185
Yamauchi, A., Ieiri, I., Kataoka, Y., Tanabe, M., Nishizaki, T., Oishi, R., Higuchi, S., Otsubo, K., & Sugimachi, K. (2002) · Transplantation · doi:10.1097/00007890-200208270-00024 · Cited by 184
Increased transcriptional activity of the CYP3A4*1B promoter variant
Amirimani, B., Ning, B., Deitz, A. C., Weber, B. L., Kadlubar, F. F., & Rebbeck, T. R. (2003) · Environmental and Molecular Mutagenesis · doi:10.1002/em.10199 · Cited by 182
Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
Huisman, M. T., Smit, J. W., & Schinkel, A. H. (2000) · AIDS · doi:10.1097/00002030-200002180-00005 · Cited by 177
Haplotypes ofCYP3A4 and their close linkage withCYP3A5 haplotypes in a Japanese population
Fukushima-Uesaka, H., Saito, Y., Watanabe, H., Shiseki, K., Saeki, M., Nakamura, T., Kurose, K., Sai, K., Komamura, K., Ueno, K., et al. (2004) · Human Mutation · doi:10.1002/humu.9210 · Cited by 166
Möller, A., Iwasaki, K., Kawamura, A., Teramura, Y., Shiraga, T., Hata, T., Schäfer, A., & Undre, N. A. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15298-1 · Cited by 165
Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands.
Cardenas, M. E., Hemenway, C., Muir, R. S., Ye, R., Fiorentino, D., & Heitman, J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06940.x · Cited by 160
Pharmacology of calcineurin antagonists
Kapturczak, M. H., Meier-Kriesche, H. U., & Kaplan, B. (2004) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.01.018 · Cited by 160
PXR: A Xenobiotic Receptor of Diverse Function Implicated in Pharmacogenetics
Zhang, B., Xie, W., & Krasowski, M. D. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.11.1695 · Cited by 160
Matsuda, S., Shibasaki, F., Takehana, K., Mori, H., Nishida, E., & Koyasu, S. (2000) · EMBO Reports · doi:10.1093/embo-reports/kvd090 · Cited by 156
Elens, L., van Schaik, R. H., Panin, N., Meyer, M. D., Wallemacq, P. E., Lison, D., Mourad, M., & Haufroid, V. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.90 · Cited by 154
Factors Influencing the Pharmacokinetics of Cyclosporine in Man
Lindholm, A. (1991) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199111000-00001 · Cited by 150
Zheng, H., Zeevi, A., Schuetz, E. G., Lamba, J. K., McCurry, K. R., Griffith, B. P., Webber, S., Ristich, J., Dauber, J. H., Iacono, A. T., et al. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003262108 · Cited by 149
Brabletz, T., Pfeuffer, I., Schorr, E., Siebelt, F., Wirth, T., & Serfling, E. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.2.1155-1162.1993 · Cited by 146
Drug Interactions with Tacrolimus
van Gelder, T. (2002) · Drug Safety · doi:10.2165/00002018-200225100-00003 · Cited by 146
Krämer, B. K., Montagnino, G., del Castillo, D., Margreiter, R., Sperschneider, H., Olbricht, C. J., Krüger, B., Ortuño, J. Á., Köhler, H., Kunzendorf, U., et al. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh739 · Cited by 144
In vitro metabolism of cyclosporine A by human kidney CYP3A5
Dai, Y., Iwanaga, K., Lin, Y. S., Hébert, M. F., Davis, C. L., Huang, W., Kharasch, E. D., & Thummel, K. E. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.07.012 · Cited by 133
de Jonge, H., Metalidis, C., Naesens, M., Lambrechts, D., & Kuypers, D. R. J. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.77 · Cited by 130
Distribution of Cyclosporin in Organ Transplant Recipients
Akhlaghi, F., & Trull, A. K. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241090-00001 · Cited by 126
de Jonge, H., de Loor, H., Verbeke, K., Vanrenterghem, Y. F. C., & Kuypers, D. R. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.109 · Cited by 120
Oneda, B., Crettol, S., Sirot, E. J., Bochud, M., Ansermot, N., & Eap, C. B. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833225e7 · Cited by 120
Kuypers, D. R. J., Naesens, M., de Jonge, H., Lerut, E., Verbeke, K., & Vanrenterghem, Y. F. C. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181e06818 · Cited by 119
Association of four DNA polymorphisms with acute rejection after kidney transplantation
Grinyo, J. M., Vanrenterghem, Y. F. C., Nashan, B., Vincenti, F. G., Ekberg, H., Lindpaintner, K., Rashford, M., Nasmyth‐Miller, C., Voulgari, A., Spleiss, O., et al. (2008) · Transplant International · doi:10.1111/j.1432-2277.2008.00679.x · Cited by 118
Capron, A., Lerut, J. P., Latinne, D., Rahier, J., Haufroid, V., & Wallemacq, P. E. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01365.x · Cited by 117
Benkali, K., Rostaing, L. P. E., Prémaud, A., Woillard, J., Saint‐Marcoux, F., Urien, S., Kamar, N., Marquet, P., & Rousseau, A. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535950-000000000-00000 · Cited by 117
Brabletz, T., Pfeuffer, I., Schorr, E., Siebelt, F., Wirth, T., & Serfling, E. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.2.1155 · Cited by 117
Capron, A., Mourad, M., Meyer, M. D., Pauw, L. D., Eddour, D. C., Latinne, D., Elens, L., Haufroid, V., & Wallemacq, P. E. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.43 · Cited by 110
Fukudo, M., Yano, I., Yoshimura, A., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f9ac01 · Cited by 108
Birdwell, K., Grady, B. J., Choi, L., Xu, H., Bian, A.-H., Denny, J., Jiang, M., Vranic, G., Basford, M., Cowan, J., et al. (2012) · Pharmacogenetics & Genomics · doi:10.1097/fpc.0b013e32834e1641 · Cited by 108
Sim, S. C., Edwards, R. J., Boobis, A. R., & Ingelman‐Sundberg, M. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000171516.84139.89 · Cited by 107
Expression of MDR1 (Multidrug Resistance) Gene and Its Protein in Normal Human Kidney
Ernest, S., Rajaraman, S., Megyesi, J. K., & Bello-Reuss, E. N. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000190289 · Cited by 107
Iwasaki, K., Shiraga, T., Nagase, K., Tozuka, Z., Kosei, N. O. D. A., Sakuma, S., FUJITSU, T., Shimatani, K., Sato, A., & Fujioka, M. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08219-4 · Cited by 106
Chiu, Y.-Y., Higaki, K., Neudeck, B. L., Barnett, J. L., Welage, L. S., & Amidon, G. L. (2003) · Pharmaceutical Research · doi:10.1023/a:1023481418576 · Cited by 106
Khanna, A. K., Cairns, V. R., & Hosenpud, J. D. (1999) · Transplantation · doi:10.1097/00007890-199902270-00021 · Cited by 102
Palkowitsch, L., Marienfeld, U., Brunner, C., Eitelhuber, A. C., Krappmann, D., & Marienfeld, R. B. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.155895 · Cited by 98
Yong-fang, H., Qiu, W., Liu, Z., Zhu, L., Liu, Z., Tu, J., Wang, D., Li, Z., He, J., Zhong, G., et al. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04492.x · Cited by 98
Qiu, X., Jiao, Z., Zhang, M., Zhong, L.-J., Hui-qi, L., Ma, C.-L., Zhang, L., & Zhong, M. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0520-8 · Cited by 89
Williams, D., & Haragsim, L. (2006) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2005.11.001 · Cited by 81
Elens, L., Bouamar, R., Hesselink, D. A., Haufroid, V., van Gelder, T., & van Schaik, R. H. N. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328351f3c1 · Cited by 77
Biliary Excretion of Cyclosporine in Liver Transplant Patients.
Venkataramanan, R., Starzl, T. E., Yang, S., et al. (1985) · PubMed · Cited by 76
Self-citationFalck, P., Åsberg, A., Guldseth, H., Bremer, S., Akhlaghi, F., Reubsaet, L., Pfeffer, P. F., Hartmann, A., & Midtvedt, K. (2008) · Transplantation · doi:10.1097/tp.0b013e31815feede · Cited by 75
Renal Transplant Immunosuppression Impairs Natural Killer Cell Function In Vitro and In Vivo
Morteau, O., Blundell, S., Chakera, A., Bennett, S. C., Christou, C. M., Mason, P. D., Cornall, R. J., & O’Callaghan, C. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013294 · Cited by 73
Multidrug Resistance Gene G1199A Polymorphism Alters Efflux Transport Activity of P-Glycoprotein
Woodahl, E. L., Yang, Z., Bui, T., Shen, D. D., & Ho, R. J. Y. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065383 · Cited by 72
Tacrolimus-Induced Alopecia in Female Kidney-Pancreas Transplant Recipients
Tricot, L., Lebb, C. L., Pillebout, E. L., Martinez, F., Legendre, C. M., & Thervet, É. (2005) · Transplantation · doi:10.1097/01.tp.0000181195.67084.94 · Cited by 71
Donor ABCB1 Variant Associates with Increased Risk for Kidney Allograft Failure
Moore, J., McKnight, A. J., Döhler, B., Simmonds, M. J., Courtney, A. E., Brand, O. J., Briggs, D., Ball, S. T., Cockwell, P., Patterson, C., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012030260 · Cited by 71
Yanagimachi, M. D., Naruto, T., Tanoshima, R., Kato, H., Yokosuka, T., Kajiwara, R., Fujii, H., Tanaka, F., Goto, H., Yagihashi, T., et al. (2009) · Clinical Transplantation · doi:10.1111/j.1399-0012.2009.01181.x · Cited by 68
IL-6 Promoter Polymorphism −174 Is Associated with New-Onset Diabetes after Transplantation
Bamoulid, J., Courivaud, C., Deschamps, M., Mercier, P., Ferrand, C., Penfornis, A., Tiberghien, P., Chalopin, J., Saas, P., & Ducloux, D. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010066 · Cited by 66
Messer, G., Weiss, E. H., & Baeuerle, P. A. (1990) · Cytokine · doi:10.1016/1043-4666(90)90046-v · Cited by 63
Cell adhesion differentially regulates the nucleocytoplasmic distribution of active MAP kinases
Aplin, A. E., Hogan, B. P., Tomeu, J., & Juliano, R. L. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.13.2781 · Cited by 62
Zhang, J., Zhang, H., Ding, X., Ma, S., & Miao, L.-Y. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1432-1 · Cited by 61
Hu, Y., Tu, J., Tan, Z., Liu, Z., Zhou, G., He, J., Wang, D., & Zhou, H. (2007) · Xenobiotica · doi:10.1080/00498250601149206 · Cited by 61
Tavira, B., García, E. C., Díaz‐Corte, C., Ortega, F., Arias, M., Torres, A., Díaz, J. M., Selgas, R., López‐Larrea, C., Campistol, J. M., et al. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.143 · Cited by 60
Genetic epidemiology of induced CYP3A4 activity
Rahmioğlu, N., Heaton, J. C., Clement, G., et al. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283498ecf · Cited by 58
Barraclough, K. A., Isbel, N. M., Kirkpatrick, C. M. J., Lee, K., Taylor, P. J., Johnson, D. W., Campbell, S. B., Leary, D. R., & Staatz, C. E. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03815.x · Cited by 53
Self-citationWoodahl, E. L., Yang, Z., Bui, T., Shen, D. D., & Ho, R. J. Y. (2005) · AIDS · doi:10.1097/01.aids.0000183626.74299.77 · Cited by 53
Shi, X., Geng, F., Jiao, Z., Cui, X.-Y., Qiu, X., & Zhong, M. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01206.x · Cited by 52
Tacrolimus and Cyclosporine Nephrotoxicity in Native Kidneys of Pancreas Transplant Recipients
Fioretto, P., Najafian, B., Sutherland, D. E. R., & Mauer, M. S. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03850510 · Cited by 51
Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral® vs Sandimmune®
Choc, M. G. (1997) · International Journal of Dermatology · doi:10.1046/j.1365-4362.36.s1.2.x · Cited by 46
Crouthamel, M. H., Wu, D. Y., Yang, Z., & Ho, R. J. Y. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20743 · Cited by 46
Herrlinger, K. R., Koç, H., Winter, S., Teml, A., Stange, E., Fellermann, K., Fritz, P., Schwab, M. G., & Schaeffeler, E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.348 · Cited by 46
Knoop, C., Thiry, P., Saint‐Marcoux, F., Rousseau, A., Marquet, P., & Estenne, M. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.00870.x · Cited by 43
García-Cerrada, M., Macias, R. M., Cubero, J. J., Benítez, J., Caravaca, F., & Gervasini, G. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1355-x · Cited by 41
Sandborn, W. J., Lawson, G. M., Cody, T. J., Porayko, M. K., Hay, E. J., Gores, G. J., Steers, J. L., Krom, R. A. F., & Wiesner, R. H. (1995) · Hepatology · doi:10.1002/hep.1840210113 · Cited by 41
Cyclosporine: advantages versus disadvantages vis-à-vis tacrolimus
Maes, B., & Vanrenterghem, Y. F. C. (2004) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.01.038 · Cited by 37
Minguillón, J., Morancho, B., Kim, S., López‐Botet, M., & Aramburu, J. F. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0904503 · Cited by 37
Wada, M. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.06.050 · Cited by 35
Cyclosporin A in rheumatoid arthritis: overview of efficacy.
Wells, G. A., & Tugwell, P. (1993) · PubMed · Cited by 33
Akhlaghi, F., Dostálek, M., Falck, P., Mendonza, A. E., Amundsen, R., Gohh, R., & Åsberg, A. (2011) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318241ac71 · Cited by 31
Kreutz, R. H., Bolbrinker, J., Beer, F. V. D. S.-D., Boeschoten, E. W., Dekker, F. W., Kain, S., Martus, P., Sietmann, A., Friedrichs, F., Stoll, M., et al. (2008) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500488 · Cited by 26
Qiu, F., Xiao-jing, H., Sun, Y., Li‐Ling, J., & Zhao, L. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70594-1 · Cited by 22
Seymen, P., Yildiz, M., Türkmen, M., Titiz, M. İ., & Seymen, H. O. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2009.09.069 · Cited by 18
Lachance, K., Barhdadi, A., Mongrain, I., Normand, V., Zakrzewski‐Jakubiak, M., Leblanc, M.-H., Racine, N., Carrier, M., Ducharme, A., Turgeon, J., et al. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283510a35 · Cited by 13
Goppelt‐Struebe, M., Esslinger, B., & Kunzendorf, U. (2003) · Clinical Transplantation · doi:10.1034/j.1399-0012.2003.02053.x · Cited by 11
Analysis of Factors Influencing Tacrolimus Levels and Immunoassay Bias in Renal Transplantation
Borrows, R., Chusney, G. D., Loucaidou, M., James, A., Goel, S., Borrows, S., Tromp, J. V., Cairns, T. D. H., Griffith, M. E., Hakim, N., et al. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007303765 · Cited by 9
Cited by
TFOS DEWS II Management and Therapy Report
Jones, L., Downie, L. E., Korb, D., Benitez-del-Castillo, J. M., Dana, R., Deng, S. X., Dong, P. N., Geerling, G., Hida, R. Y., Liu, Y., et al. (2017) · The Ocular Surface · doi:10.1016/j.jtos.2017.05.006 · Cited by 1,422
Warne, J., Pryce, G., Hill, J. M., Shi, X., Lennerås, F., Puentes, F., Kip, M., Hilditch, L., Walker, P., Simone, M. I., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.700385 · Cited by 99
Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers
Alloway, R. R., Trofe-Clark, J., Brennan, D. C., Kerr, J., Cohen, E. A., Meier-Kriesche, U., Stevens, D. R., Moten, M. A., & Momper, J. D. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000773 · Cited by 10
Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation
Rao, N., Carcella, T., Patel, N., Bartlett, F., Posadas, M. A., Casey, M., Dubay, D. A., & Taber, D. J. (2023) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000494 · Cited by 5
Metadata
- Authors
- Barbarino, J. M., Staatz, C. E., Venkataramanan, R., Klein, T. E., & Altman, R. B.
- Venue
- Pharmacogenetics and Genomics
- Published
- 2013-10
- Volume
- 23
- Issue
- 10
- Pages
- 563-585
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W2036807791
- Cited by
- 257
- References
- 139
- FWCI
- 10.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.